EMERGENT BIOSOLUTIONS INC. (EBS) Quick Ratio
- Quick ratio · latest quarter: Value (m); Formula and calculation Cash, cash equivalents, current marketable securities and trade receivables / current liabilities. Period ending 2026-06-30..
Quick ratio
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Quick ratio · latest quarter | (m) | Cash, cash equivalents, current marketable securities and trade receivables / current liabilities. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Cash, securities and trade receivables | (m) | Cash and Cash Equivalents, at Carrying Value · Debt Securities, Available-for-sale, Current · Accounts Receivable, after Allowance for Credit Loss, Current |
| Current obligations | 122.80M USD | Liabilities, Current |
| Cash and equivalents | 139.70M USD | Cash and Cash Equivalents, at Carrying Value |
| Short-term securities | (m) | Debt Securities, Available-for-sale, Current |
| Customer receivables | 190.00M USD | Accounts Receivable, after Allowance for Credit Loss, Current |
| Inventory · excluded from quick assets | 303.60M USD | Inventory, Net |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Cash, securities and trade receivables (USD) | Current obligations (USD) | Cash and equivalents (USD) | Short-term securities (USD) | Customer receivables (USD) | Inventory · excluded from quick assets (USD) | Quick ratio |
|---|---|---|---|---|---|---|---|
| 2026-06-30 | (m) | $122.80M | $139.70M | (m) | $190.00M | $303.60M | (m) |
| 2026-03-31 | (m) | $148.70M | $160.30M | (m) | $121.60M | $327.60M | (m) |
| 2025-12-31 | (m) | $132.20M | $205.40M | (m) | $84.20M | $343.40M | (m) |
| 2025-09-30 | (m) | $136.50M | $245.50M | (m) | $149.50M | $356.30M | (m) |
| 2025-06-30 | (m) | $127.10M | $267.30M | (m) | $79.80M | $338.60M | (m) |
| 2025-03-31 | (m) | $111.90M | $149.10M | (m) | $203.70M | $314.00M | (m) |
| 2024-12-31 | (m) | $162.40M | $99.50M | (m) | $154.50M | $311.70M | (m) |
| 2024-09-30 | (m) | $229.90M | $149.90M | (m) | $121.30M | $322.70M | (m) |
| 2024-06-30 | (m) | $619.70M | $69.70M | (m) | $196.30M | $317.50M | (m) |
| 2024-03-31 | (m) | $630.20M | $78.50M | (m) | $233.50M | $333.40M | (m) |
| 2023-12-31 | (m) | $651.30M | $111.70M | (m) | $191.00M | $328.90M | (m) |
| 2023-09-30 | (m) | $664.00M | $87.80M | (m) | $216.50M | $354.10M | (m) |
| 2023-06-30 | (m) | $693.20M | $88.60M | (m) | $290.10M | $354.30M | (m) |
| 2023-03-31 | (m) | $1.22B | $430.20M | (m) | $155.90M | $367.90M | (m) |
| 2022-12-31 | (m) | $1.23B | $642.60M | (m) | $158.40M | $351.80M | (m) |
| 2022-09-30 | (m) | $268.40M | $240.90M | (m) | $191.30M | $546.30M | (m) |
| 2022-06-30 | (m) | $276.70M | $358.10M | (m) | $175.00M | $425.50M | (m) |
| 2022-03-31 | (m) | $249.20M | $435.80M | (m) | $181.80M | $400.70M | (m) |
| 2021-12-31 | (m) | $373.80M | $576.10M | (m) | $274.70M | $350.80M | (m) |
| 2021-09-30 | (m) | $365.40M | $403.80M | (m) | $254.60M | $364.60M | (m) |
| 2021-06-30 | (m) | $377.80M | $447.50M | (m) | $261.90M | $386.40M | (m) |
| 2021-03-31 | (m) | $370.20M | $547.80M | (m) | $184.40M | $406.50M | (m) |
| 2020-12-31 | (m) | $384.50M | $621.30M | (m) | $230.90M | $307.00M | (m) |
| 2020-09-30 | (m) | $299.30M | $415.00M | (m) | $196.10M | $270.10M | (m) |
| 2020-06-30 | (m) | $293.70M | $268.80M | (m) | $258.60M | $236.20M | (m) |
| 2020-03-31 | (m) | $207.10M | $181.50M | (m) | $162.50M | $248.10M | (m) |
| 2019-12-31 | (m) | $216.30M | $167.80M | (m) | $270.70M | $222.50M | (m) |
| 2019-09-30 | (m) | $275.30M | $139.20M | (m) | $281.20M | $230.20M | (m) |
| 2019-06-30 | (m) | $301.20M | $177.40M | (m) | $218.10M | $232.00M | (m) |
| 2019-03-31 | (m) | $248.40M | $137.20M | (m) | $121.50M | $211.00M | (m) |
| 2018-12-31 | (m) | $200.40M | $112.20M | (m) | $262.50M | $205.80M | (m) |
| 2018-09-30 | (m) | $102.01M | $339.36M | (m) | $76.95M | $125.75M | (m) |
| 2018-06-30 | (m) | $96.81M | $190.24M | (m) | $189.49M | $139.37M | (m) |
| 2018-03-31 | (m) | $86.87M | $163.61M | (m) | $122.09M | $155.20M | (m) |
| 2017-12-31 | (m) | $100.07M | $178.29M | (m) | $143.65M | $142.81M | (m) |
| 2017-09-30 | (m) | $75.43M | $340.99M | (m) | $129.36M | $68.89M | (m) |
| 2017-06-30 | (m) | $72.93M | $315.63M | (m) | $102.51M | $70.53M | (m) |
| 2017-03-31 | (m) | $67.71M | $270.17M | (m) | $128.08M | $70.73M | (m) |
| 2016-12-31 | (m) | $105.86M | $271.51M | (m) | $138.48M | $74.00M | (m) |
| 2016-09-30 | (m) | $110.31M | $298.93M | (m) | $69.63M | $81.16M | (m) |
| 2016-06-30 | (m) | $103.86M | $333.39M | (m) | $66.75M | $96.67M | (m) |
| 2016-03-31 | (m) | $90.45M | $341.02M | (m) | $69.56M | $88.20M | (m) |
| 2015-12-31 | (m) | $99.61M | $312.80M | (m) | $120.77M | $76.94M | (m) |
| 2015-09-30 | (m) | $88.72M | $308.72M | (m) | $57.04M | $80.07M | (m) |
| 2015-06-30 | (m) | $86.96M | $214.84M | (m) | $99.72M | $84.71M | (m) |
| 2015-03-31 | (m) | $80.30M | $216.51M | (m) | $64.06M | $82.13M | (m) |
| 2014-12-31 | (m) | $92.94M | $280.50M | (m) | $58.83M | $65.67M | (m) |
| 2014-09-30 | (m) | $81.42M | $242.25M | (m) | $44.11M | $62.53M | (m) |
| 2014-06-30 | (m) | $76.43M | $168.13M | (m) | $78.27M | $66.03M | (m) |
| 2014-03-31 | (m) | $72.32M | $160.22M | (m) | $62.94M | $71.27M | (m) |
| 2013-12-31 | (m) | $56.65M | $179.34M | (m) | $60.59M | $14.64M | (m) |
| 2013-09-30 | (m) | $56.63M | $172.56M | (m) | $30.09M | $16.32M | (m) |
| 2013-06-30 | (m) | $48.78M | $156.24M | (m) | $54.37M | $18.58M | (m) |
| 2013-03-31 | (m) | $43.54M | $130.24M | (m) | $62.96M | $22.15M | (m) |
| 2012-12-31 | $237.71M | $61.91M | $141.67M | $0.00 | $96.04M | $15.16M | 3.84× |
| 2012-09-30 | $214.99M | $50.57M | $197.90M | $0.00 | $17.09M | $18.25M | 4.25× |
| 2012-06-30 | $208.66M | $44.47M | $161.84M | $0.00 | $46.81M | $16.01M | 4.69× |
| 2012-03-31 | $194.08M | $42.99M | $150.43M | $0.00 | $43.65M | $17.32M | 4.51× |
| 2011-12-31 | $220.02M | $71.05M | $143.90M | $1.97M | $74.15M | $14.66M | 3.10× |
| 2011-09-30 | $177.84M | $68.93M | $125.35M | $3.50M | $48.99M | $17.98M | 2.58× |
| 2011-06-30 | $174.41M | $72.50M | $122.09M | $5.05M | $47.26M | $17.26M | 2.41× |
| 2011-03-31 | (m) | (m) | $136.93M | (m) | (m) | (m) | (m) |
| 2010-12-31 | $210.37M | $75.72M | $169.02M | $2.03M | $39.33M | $12.72M | 2.78× |
| 2010-09-30 | (m) | (m) | $151.23M | (m) | (m) | (m) | (m) |
| 2010-06-30 | (m) | (m) | $102.19M | (m) | (m) | (m) | (m) |
| 2009-12-31 | (m) | (m) | $102.92M | (m) | (m) | (m) | (m) |
| 2008-12-31 | (m) | (m) | $91.47M | (m) | (m) | (m) | (m) |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ENANTA PHARMACEUTICALS INC (ENTA) | United States | $0.349B | -6.72 |
| Larimar Therapeutics, Inc. (LRMR) | United States | $0.344B | -1.83 |
| Vogenx, Inc. (VOGX) | United States | $0.355B | |
| Benitec Biopharma Inc. (BNTC) | United States | $0.337B | -10.08 |
| BioAge Labs, Inc. (BIOA) | United States | $0.333B | -11.88 |
| BridgeBio Oncology Therapeutics, Inc. (BBOT) | United States | $0.320B | -3.35 |
| Evommune, Inc. (EVMN) | United States | $0.320B | -5.10 |
| Prelude Therapeutics Inc (PRLD) | United States | $0.318B | -7.01 |
| ABEONA THERAPEUTICS INC. (ABEO) | United States | $0.312B | -5.63 |
| Rezolute, Inc. (RZLT) | United States | $0.382B | -6.45 |